Background. Serum urate (SUA) level is affected by alteration in urinary reabsorption caused by clinically important drugs; however, there are no experimental models suitable to assess their effect on renal reabsorption. We, therefore, aimed to establish an experimental system co-expressing the urate transporters URAT1 (SLC22A12) and URATv1 (SLC2A9) (designated UUv cells) at the apical and basolateral membranes, respectively. Methods. Apical uptake and vectorial transport of [ 14 C]urate in the apical-to-basolateral direction in UUv cells were measured in the presence or absence of uricosuric benzbromarone or anti-uricosuric trans-stimulators. Results. The urate permeability in the apical-to-basolateral direction remarkably increased by 7.0-fold in UUv cells, compared with non-transfected mock cells. The apical-to-basolateral transport was cis-inhibited by benzbromarone, but transstimulated by pyrazinecarboxylic acid and monocarboxylates such as nicotinate and lactate. Furthermore, salicylate showed both trans-stimulation and cis-inhibition in the urate transport at low and high concentrations, respectively. Finally, coexpression of URAT1 and URATv1 in human kidney epithelial cells was exhibited immunohistochemically. Conclusions. It is demonstrated that functional cooperation of URAT1 and URATv1 is essential for renal reabsorption of urate, and in the established system influence of drugs on SUA is reflected in the alteration of urate permeability across the renal tubular epithelial cells.
A B S T R AC T
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I N T RO D U C T I O N
In humans, urate is the end product of purine nucleoside metabolism, which is not further metabolized to allantoin due to lack of uricase activity. Since the serum urate (SUA) level is balanced between hepatic production and urinary, partly intestinal, excretion [1, 2] , a decrease in an excretion rate of urate is considered to elevate SUA, resulting in hyperuricaemia. Hyperuricaemia is an independent risk factor for gout attack and cardiovascular diseases [3] and is associated with many lifestyle-related diseases, including hypertension, obesity and chronic kidney disease [4] [5] [6] [7] [8] . Therefore, management of SUA is clinically important to avoid complications related to hyperuricaemia.
Although renal handling of urate is not yet fully understood, ∼90% of glomerularly filtrated urate is reabsorbed at proximal tubular cells. Urate reabsorption is achieved by urate uptake from the urinary lumen and its secretion to blood vessels. Several transporter proteins expressed in the apical membranes of the proximal tubular cells are involved in urate uptake, including urate-anion exchanger URAT1 (SLC22A12) and organic anion transporter (OAT) 4 and 10 [9] [10] [11] . In contrast to unestablished roles of OAT4 and OAT10, contribution of URAT1 to urate uptake has been clearly defined in terms of clinical pharmacology and pharmacogenomics. In particular, benzbromarone, used to treat patients with hyperuricaemia, exhibits a uricosuric effect due to an inhibition of URAT1, whereas pyrazinecarboxylic acid (PZA), an active metabolite of pyrazinamide used in treatment for tuberculosis, increases SUA based on its transstimulatory effect on URAT1 activity [11] . We have shown that membrane transporters play a critical role in tissue disposition of urate [2, 10, 12] and that major angiotensin II receptor blockers (ARBs) could interfere with URAT1-mediated urate transport, resulting in the alteration of SUA [13, 14] . Many other drugs, including diuretics and calcium channel blockers, can also alter SUA in a similar mode of action [15, 16] . At the basolateral membranes, initially isolated glucose transporter, GLUT9 (SLC2A9), has been characterized as a voltage-dependent glucose-urate exchanger and also known as URATv1. URATv1 significantly contributes to translocate urate from proximal tubular cells into systemic circulation [17] [18] [19] , because loss-of-function mutations of URATv1 were shown to associate with a decrease in SUA in humans [19, 20] . Thus, both URAT1 and URATv1 play critical roles in urate reabsorption. Despite their roles, there exists no experimental model suitable to evaluate the influence of drugs on urate reabsorption.
In the present study, we, therefore, aimed to create an experimental model that mimics renal reabsorption of urate mediated by URAT1 and URATv1 across Madin-Darby canine kidney (MDCK II) cells, and examined whether the effect of drugs on urinary reabsorption is reflected in alteration in transcellular transport of urate across the monolayer. Besides, immunolocalization of both transporters was assessed in human kidney sections. Our results indicate that this newly established model is applicable to predict the impact of uricosuric and anti-uricosuric drugs on SUA.
M AT E R I A L S A N D M E T H O D S
Chemicals and animals [ 14 C]Urate (1.96 TBq/mol) was purchased from Moravek Biochemicals (Brea, CA, USA). Benzbromarone and PZA were obtained from Wako Pure Chemical (Osaka, Japan). Rabbit polyclonal antibodies to human URAT1 and URATv1 were purchased from Medical Biological Laboratories (Nagoya, Japan). All other reagents were reagent grade products from Sigma-Aldrich (St Louis, MO, USA), Wako Pure Chemicals or Nacalai Tesque (Kyoto, Japan).
Cell culture MDCK II cells were obtained from American Type Culture Collection (Manassas, VA), and transfected with plasmid DNA ( pcDNA3.1) harbouring geneticin-resistant gene alone (MDCK/Mock, or M) or containing URAT1 cDNA [21] , or the pcDNA3.1/Hygro containing URATv1 cDNA (isoform 1) and hygromycin B-resistant gene [18] . Transformants with URAT1 and URATv1 were selected with geneticin (G418) or hygromycin B, respectively. The established cell clones expressing URAT1 and URATv1 were designated as MDCK/U (U) and MDCK/Uv (Uv), respectively. The U cells were further transfected with pcDNA3.1/Hygro containing URATv1 cDNA and then selected with hygromycin B. The isolated clones were screened by transcellular urate transport activity and immunolocalization of URTA1 and URATv1 (designated as MDCK/UUv or UUv). All cell lines were grown in Dulbecco's modified Eagle's medium (Life Technology, Carlsbad, CA, USA) supplemented with 10% (v/ v) fetal bovine serum (SAFC Biosciences, Hampshire, UK) at 37°C in an atmosphere of 5% CO 2 .
Immunofluorescence staining and microscopy MDCK cells were plated on coverslips at a density of 1 × 10 5 cells/well and then fixed in 4% paraformaldehyde. [22] . Cells were cultured on Transwell® filter membrane inserts (BD, Franklin Lakes, NJ, USA) at a density of 2 × 10 5 cells/well for 5 days before transport study. The transport was initiated by adding the transport buffer containing 
the transport assay using [
14 C]urate (20 μM) as described previously [12] . To examine the cis-effect of test compounds, uptake was initiated by placing the oocytes into chloride ion-free ND96 (96 mM Na-gluconate, 2 mM K-gluconate, 1 mM Mg-gluconate, 5 mM HEPES, pH 7.4) at room temperature. For trans-stimulation of urate uptake, the oocytes were injected with test compound solution (50 nL) just before initiation of the assay. At the end of the uptake, the uptake reaction was stopped by washing the oocytes with ice-cold chloride ion-free ND96, and then the oocytes were solubilized in 1 N NaOH solution. Total radioactivity was measured using a liquid scintillation counter (Aloka).
Data analysis
Inhibitory effects of drugs on uptake or transcellular transport of urate were calculated by non-linear least-squares regression analysis using KaleidaGraph 4.0.2 (Synergy Software, Reading, PA, USA), according to the following equation: percentage of control = 100 × IC 50 /(IC 50 + I), where IC 50 and I are the 50% inhibitory concentration and the concentration of inhibitor used, respectively. All data are presented as the mean ± SE. Statistical significance was examined with Student's t-test (P < 0.05).
R E S U LT S
Immunolocalization of URAT1 and URATv1, and characterization of urate transport in UUv cells Immunolocalization of both URAT1 and URATv1 proteins in the UUv cells was examined with a confocal laser scanning microscope (Figure 1 ). Red fluorescence corresponding to URAT1 expression was localized at the apical side ( Figure 1A , left), whereas green fluorescence for URATv1 was detected mainly at the basolateral side of the cells ( Figure 1B, right) . Under the same conditions, neither significant immunofluorescence for URAT1 nor URATv1 was observed in M cells (Figure 1 , right panels). Apical uptake of urate was determined in UUv and U cells and compared with that in M cells. As shown in Figure 2A , urate uptake was 1.63-and 1.72-fold higher in UUv and U cells than in M cells, respectively, in the presence of chloride ions. The uptake was greater in the absence of chloride ions (5.23-and 9.61-fold, respectively; Table 1 ). This effect could be because URAT1-mediated influx of urate is driven by an outward gradient of chloride ion concentration. Then, transcellular transport of urate was examined in the four cell lines (Table 1, Figure 2B ). The urate permeability in the direction of the apical to the basolateral side remarkably increased by 7.0-fold in UUv cells, compared with M cells, whereas such an Figure 2C , transport of urate across the monolayer of UUv cells was compared with the opposite direction. The transport in the direction of basolateral to apical was also higher than that compared with M cells, but weaker than that in the direction of apical to basolateral side. These results demonstrate that cooperation of URAT1 and URATv1 is essential for reabsorption of urate.
Influence of drugs on SUA in UUv cells
To determine the effect of drugs on urate transport across monolayer of UUv cells, benzbromarone, PZA and salicylate that presumably influence the SUA level by altering the reabsorption rate of urate was used in the following experiments. First, benzbromarone, which exerts an uricosuric effect by inhibiting URAT1, was tested for its potential to inhibit the apical-to-basolateral transport of urate (Figure 3) . Urate transport barely detected in U cells was not affected by benzbromarone. In UUv cells, it inhibited transcellular transport of urate in a concentration-dependent manner with IC 50 of 119 nM ( Figure 3A and B) . This was comparable with the IC 50 values for the cis-inhibitory effect on apical uptake of urate by U (123 nM) and UUv (231 nM) cells ( Figure 3C ).
Next, PZA, which increases the SUA level with being exchanged with urate via UART1, was examined in UUv cells. Urate transport was significantly stimulated by PZA added on the basolateral side as its concentration increased, showing its trans-stimulatory effect ( Figure 4A ). Preloaded PZA exhibited such effect on apical uptake of urate in both UUv and U cells ( Figure 4B ). In addition, trans-stimulation effect was similarly observed by lactate and nicotinate, which are endogenous counter substrates of URAT1, in UUv cells ( Figure 4C) .
Finally, the effect of salicylate on urate transport was investigated because it increases SUA at a lower dose, but decreases it at a higher dose in clinical settings [23] . We, therefore, examined cis-inhibitory and trans-stimulatory effects of salicylate on urate uptake in Xenopus oocytes expressing URAT1. Salicylate inhibited urate uptake in a concentration-dependent manner with an IC 50 (106 ± 11 μM, Figure 5A ). Urate uptake increased nearly 50% in the oocytes injected with salicylate (1 mM) immediately before initiating the uptake assay, whereas it was not in the oocytes injected with salicylurate that is generated from salicylate formed in vivo and not a substrate of URAT1. Namely, salicylate transstimulated urate influx mediated by URAT1. Then, the effect of salicylate on apical to basolateral transport of urate across monolayer of UUv cells was measured at different concentrations ( Figure 5C ). At the lower concentrations of salicylate (1 and 10 μM), urate transport was stimulated by 42.3 and 18.2%, respectively, whereas at the higher concentrations (100 and 1000 μM), it was reduced by 34.0 and 62.2%, respectively, compared with that in the absence of salicylate. These results suggest that an intriguing dose-dependent effect of salicylate on SUA is attributed to its pharmacological effect on vectorial transport of urate mediated by URAT1 and URATv1.
Immunolocalization of URAT1 and URATv1 in human proximal tubules
To study coexpression of URAT1 and URATv1 in proximal tubular cells in the human kidney, we examined the immunolocalization of URATv1 and URAT1 in paraffin-embedded renal sections ( Figure 6 ). Nuclei were stained with Hoechst 33342 (blue, Figure 6A ), and URAT1 and URATv1 were visualized in green and red colours, respectively ( Figures 6B and C) . URAT1 expression was likely confined to the apical membranes of proximal tubular cells, whereas URATv1 expression was predominantly observed at the basolateral membranes. The merged picture displays such a coexpression of the both proteins in the same proximal tubular cell ( Figure 6D ).
D I S C U S S I O N
Our results indicate that functional cooperation of apical URAT1 and basolateral URATv1 is essential for renal reabsorption of urate in the human kidney, and that the newly established UUv cell line would be an experimental model suitable to assess the pharmacological effect of uricosuric and anti-uricosuric drugs on urate reabsorption.
Currently, there is no experimental model available to predict the effect of pharmacological inhibition of urate reabsorption on SUA. Experimental animals, in general use, such as rats and mice, may not be appropriate because of differences between species related to uricase activity. We reported that URAT1 functions in the rat kidney [22] ; however, rat proximal tubular in primary culture, for this purpose, is useless because URAT1 expression was lost [24] . Human kidney 2 (HK-2) cells retain the functional characteristics of the human renal proximal tubular epithelium; however, they are not appropriate to assess transcellular transport of urate. Because the creation of an experimental model to assess the influence of drugs on SUA may help us to develop safe and efficient uricosuric agents, this study was conceived. In humans, since loss-offunction mutations of URAT1 [11, 25, 26] and URATv1 [19, 20] reduced SUA, independently, they are considered to be the determinant factors of reabsorption, although other OATs including OAT4 [10] and OAT10 [27] might be involved. In addition, reabsorption predominates over secretion in urinary excretion of urate; therefore, urate reabsorption cooperatively maintained by URAT1 and URATv1 is focused on for the convenient experimental model.
In UUv cells, transcellular transport of urate was significantly enhanced, whereas it is negligible in U or UUv cells compared with M cells (Figure 2) . Accordingly, for the first time, functional cooperation of URAT1 and URATv1 was experimentally demonstrated to be essential for urate reabsorption. Benzbromarone exhibited a cis-inhibitory effect on urate uptake by URAT1 (Figure 3) . The IC 50 for urate uptake by U cells was 123 nM, close to the reported IC 50 in Xenopus oocytes expressing URAT1 [11] . The determined IC 50 (231 nM) in UUv cells was ∼2-fold higher than that in U cells, and this may result from the leakage of intracellular uric acid via basolaterally expressed URATv1. Furthermore, a transstimulatory effect of PZA was clearly seen after pre-exposure of UUv cells to PZA (Figure 4) . These results are in good agreement with the previous findings in Xenopus oocytes [11] , and URAT1-transfected HEK cells [28] , suggesting that the established UUv cell line can be a good model to mirror the influence of drug on URAT1 in alteration in SUA levels. On the other hand, this system may also be useful to evaluate the effect of drugs on URATv1. Since no particular compounds are known to specifically inhibit to URATv1, we were unable to make a case for such a drug that affects URATv1 in the present study. To date, since many clinically important drugs, including ARBs [2, 10, 12, 15] , diuretics and calcium channel blockers [15, 16] , have been suggested to modulate SUA, our method may be applicable to clarify their mode of actions in future.
Early studies by Yü and Gutman [23] described a dosedependent action of salicylate on the SUA level as a 'paradoxical effect'. In the report, fractional excretion of urate decreased when total plasma salicylate concentration was relatively low (∼280 μM), whereas it increased as the concentration was elevated (up to 1100 μM). Since salicylate, but not its metabolite of salicylurate, showed a stimulatory effect on URAT1-mediated urate uptake, salicylate is further studied to 
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O R I G I N A L A R T I C L E
U R A T 1 a n d U R A T v 1 c o o p e r a t i o n i n u r a t e r e a b s o r p t i o n evaluate clinically observed 'paradoxical effect' ( Figure 5B ). Taking its plasma protein binding into account, the free concentration is equivalent to 70 μM for the total concentration of 280 μM, and to 275 μM for 1100 μM. In the present study, URAT1-mediated apical uptake of urate was inhibited in a concentration-dependent manner of salicylate, and transstimulation of urate was observed in URAT1-expressing oocytes injected with 1.0 mM salicylate (intra-oocyte concentration was estimated at 44 μM based on the reported cellular volume [13] ) ( Figure 5A and B) . Furthermore, transcellular transport of urate in UUv cells increased in the presence of up to 100 μM salicylate, whereas a higher loading of urate (>100 μM) caused a significant decrease in the transport ( Figure 5C ). These observations agree with a previous report which that salicylate is an exchange substrate to facilitate urate reabsorption [29] . The cis-inhibitory effect of salicylate on URAT1-mediated transport of urate may exceed its transstimulatory effect at a certain concentration. Probably, salicylate at higher concentration predominantly contributes to a decrease in influx of urate by URAT1, lowering the SUA level. Since salicylate was reported to be neither substrate nor modulator of URATv1 [18] at the range of concentration used, salicylate is supposed to be nothing to do with URATv1-mediated urate transport when urate is translocated across the UUv cells. This 'paradoxical effect' may be accounted for by a concentration-dependent effect of salicylate on vectorial transport of urate in proximal tubular cells, although other unknown factors remain unclear.
Although the established UUv cells are an artificial system co-expressing URAT1 at the apical and URATv1 at the basolateral side, respectively (Figure 1 ), our result clearly shows such an immunolocalization of URAT1 and URATv1 proteins in human kidney section ( Figure 6 ). The previous report suggests that URAT1 is expressed specifically in the apical membrane [11] ; however, intracellular localization of URATv1 may differ between their isoforms. Indeed, the presented immunohistochemistry indicates a weak signal at the apical membranes with anti-URATv1 antibody ( Figure 6C ), which might be attributed to the expression of the N-terminally truncated form of URATv1, known as isoform 2 [30] . In contrast, a robust expression detected at the basolateral side is thought to be due to its isoform 1 ( Figure 6C ). The isoform 2 has been speculated to be involved in urate secretion; however, current information does not fully support its contribution to intracellular disposition of urate in proximal tubular cells. Although the physiological role of the isoform 2 has to be calcified in future, our present study represents the first evidence that both URAT1 and URATv1 are expressed in the same epithelial cell in human proximal tubules, and provides a rationale for their cooperation under physiological condition in humans.
CO N C L U S I O N
MDCK II cells expressing both URAT1 at the apical membrane and URATv1 at the basolateral membrane exhibit vectorial transport of urate, which was not detected in cells expressing either one. The influence of drugs on SUA was well reflected in the changes in net apical-to-basolateral URAT1-and URATv1-mediated transport of urate in UUv cells, suggesting that this experimental model can be feasible to predict SUA from an observed pharmacological intervention of urate reabsorption, taking consideration coexpression of both transporters in human kidney cells. This approach may serve as a helpful tool to obtain information regarding the uricosuric effect of drugs as well to predict their effect on SUA.
AC K N OW L E D G E M E N T S
This work was supported by a grant (KAKENHI 21390044) to Ikumi Tamai from the Japan Society for the Promotion of Science. We thank Ms. Mayuko Yoshifuji at the Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences, Kanazawa University, for technical assistance.
CO N F L I C T O F I N T E R E S T S TAT E M E N T
None declared. Any results presented in this paper have not been published previously in whole or part, except in abstract format.
R E F E R E N C E S

